Print

ADMA Biologics, Inc. Completes Enrollment of Phase 3 Study for RI-002  
11/4/2013 10:03:55 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

RAMSEY, N.J.--(BUSINESS WIRE)--ADMA Biologics, Inc. (OTCQB:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced the completion of enrollment for its Phase III clinical study of RI-002. This study is designed to evaluate the efficacy and safety of RI-002 as a novel immune globulin for the treatment of patients who are affected by Primary Immune Deficiency Diseases (PIDD). ADMA expects to have preliminary Phase III data in the fourth quarter of 2014.

Help employers find you! Check out all the jobs and post your resume.

//-->